Company Overview and News

3
Insurers bolster dementia insurance offerings as Japan grays

2018-08-19 japantimes.co.jp
Insurers are competing to offer dementia insurance products and services as the population continues to rapidly gray.
MET MET 8630

26
48 Of 104 S&P 500 'Safer' Dividend Stocks Yield 3% To 6.35% For August

2018-08-19 seekingalpha - 1
48 of 104 S&P 500 Index top-yield dividend stocks were labeled as "safer" for dividends because they showed positive one-year returns, and free cash-flow yields greater than their dividend-yields 8/15/18.
HCN PM PFG MET STX OPRF PRU VZA PM IP AVGO WELL LEG MO VTR PRU INPAP PFK O PRH CVX VZ SPG BRCM PJH IVZ

4
MetLife Ties Up With State Street to Buoy Investment Business

2018-08-17 zacks
MetLife Investment Management — the institutional asset management platform for MetLife, Inc. (MET - Free Report) — has tied up with State Street Corporation (STT - Free Report) .
STT MET RDN FAF NMIH Y

3
MET / MetLife, Inc. 8-K (Current Report)

2018-08-15 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
MET

4
Sticking With The Story - The Idea Guide

2018-08-11 seekingalpha
Tesla's antics overwhelmed the market this week, but we published a few ideas that involve persistence and twists and turns but not quite as much attention.
BHF SNHFF MET TPL ARES

11
Top Stock Reports: Chevron, General Dynamics, Emerson Electric & More

2018-08-09 zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features updated research reports on 16 major stocks, including Chevron (CVX), General Dynamics (GD) and Emerson Electric (EMR). These research reports have been hand-picked from roughly 70 reports published by our analyst team today.
BRK.A GD AVF AMT XOM CVX MET AIG 8685

5
2 Funds to Gain From Trump???s New Health Insurance Rule

2018-08-09 zacks
The Trump administration recently released the final rule pertaining to short-term and limited-duration insurance coverages. The new order provides cheaper and effective short-term health plans to individuals and businesses that find policies under Obamacare unaffordable.
PRU GD AVF PFK MET FSPCX AIG MET PRH CB 8685 PJH

17
Here's Why Einhorn Is Wrong On Brighthouse Financial

2018-08-08 seekingalpha
Bulls are missing the big picture as Brighthouse Financial is generating huge losses, not the profits they imagine.
BHF MET GM

3
Insurance ETFs Looking Good Post Q2 Earnings

2018-08-08 zacks
The insurance industry has performed well this reporting cycle with robust earnings from leading players. Prominent players such as MetLife (MET - Free Report) , Chubb Corp (CB - Free Report) and Allstate (ALL - Free Report) surpassed earnings and revenue estimates. While American International (AIG - Free Report) and Travelers (TRV - Free Report) missed earnings estimates, Aflac (AFL - Free Report) lagged revenue estimates.
IAK PRU ALL AFL KIE PRH PFK MET CB PRU PJH

3
3
MET / MetLife, Inc. / BOARD OF DIRECTORS OF METLIFE INC - AMENDMENT NO. 74 TO SCHEDULE 13D (Activist Investment)

2018-08-08 sec.gov
Amendment No. 74 to Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
MET

3
MET / MetLife, Inc. / BOARD OF DIRECTORS OF METLIFE INC - AMENDMENT NO. 74 TO SCHEDULE 13D (Activist Investment)

2018-08-08 sec.gov
Amendment No. 74 to Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
MET

4
MetLife: A Lot To Like Here, If You Are Able To Wait Out The Storm

2018-08-05 seekingalpha - 1
This insurance company is still dealing with the fallout from its internal control issues but, in my opinion, MET shares are worth a look at today's valuation.
RIS MET

3
MetLife (MET) Q2 2018 Results - Earnings Call Transcript

2018-08-02 seekingalpha
Ladies and gentlemen, thank you for standing by. Welcome to the MetLife Second Quarter 2018 Earnings Release Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Instructions will be given at that time. As a reminder, this conference is being recorded.
RIS BHF MET

4
MetLife (MET) Q2 Earnings & Revenues Top Estimates, Rise Y/Y

2018-08-02 zacks
MetLife, Inc.’s (MET - Free Report) second-quarter 2018 operating earnings of $1.30 per share beat the Zacks Consensus Estimate of $1.17 by 11.1%. The bottom line improved 25% year over year on prudent underwriting and expense management.
BHF HIG RDN MET ENR HGH MTG

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

CUSIP: 59156R108